ABSTRACT: Twenty-eight new substituted N-phenyl ureidobenzenesulfonate (PUB-SO) and 18 N-phenylureidobenzenesulfonamide (PUB-SA) derivatives were prepared. Several PUBSOs exhibited antiproliferative activity at the micromolar level against the HT-29, M21, and MCF-7 cell lines and blocked cell cycle progression in S-phase similarly to cisplatin. In addition, PUB-SOs induced histone H2AX (γH2AX) phosphorylation, indicating that these molecules induce DNA double-strand breaks. In contrast, PUB-SAs were less active than PUB-SOs and did not block cell cycle progression in S-phase. Finally, PUB-SOs 4 and 46 exhibited potent antitumor activity in HT-1080 fibrosarcoma cells grafted onto chick chorioallantoic membranes, which was similar to cisplatin and combretastatin A-4 and without significant toxicity toward chick embryos. These new compounds are members of a promising new class of anticancer agents.
■ INTRODUCTION
N-Phenyl-N′-(2-chloroethyl)ureas (1) are members of a class of potent antiproliferative agents acting across a large panel of tumor cell lines and in several animal cancer models ( Figure 1 ). Several subsets of these monoalkylating agents were shown to bind covalently to proteins such as β II -tubulin, 1−7 thioredoxin-1, 8−10 prohibitin-1, 11 and mitochondrial voltage-dependent anion channel, 12 leading to arrest of cell cycle progression in either G 2 /M or G 0 /G 1 phase. By use of matrix-assisted laser desorption ionization and electrospray mass spectrometry, Nphenyl-N′-(2-chloroethyl)ureas exhibiting antimicrotubule activity were shown to bind covalently to microtubules via a unique mechanism of nucleophilic addition involving the esterification of a Glu residue at position 198 of human β-tubulin (Gluβ198). 13 Of interest, Gluβ198, which is located in a small pocket adjacent to the colchicine-binding site, is involved in microtubule stability and dynamics and is also associated with a mechanism of resistance to Taxotere (docetaxel). 14, 15 With the objective of developing anticancer agents with optimal biopharmaceutical properties and lower toxicity, we recently modified the structure of the N-phenyl-N′-(2-chloroethyl)urea scaffold by the addition of a benzenesulfonate group and cyclization of the 2-chloroethylurea (CEU) moiety into a 1-phenylimidazolidin-2-one heterocycle. The latter modifications led to a novel class of potent antimicrotubule agents designated as phenyl 4-(2-oxoimidazolidin-1-yl)-benzenesulfonates (PIB-SOs, 2).
16 PIB-SOs, molecules containing an imidazolidonyl ring, exhibited antiproliferative activities in the low nanomolar range, blocked cell cycle progression in G 2 /M phase, and bound to the colchicinebinding site, leading to cytoskeleton disruption and apoptosis.
Finally, PIB-SOs inhibit angiogenesis and tumor growth in the chick chorioallantoic membrane (CAM) assay at levels comparable to combretastatin A-4 (CA-4, 3) and exhibit low to very low toxicity toward chick embryos. 16 The assessment of the antiproliferative activity and the effect on cell cycle progression of the subset (compounds 4−10) of novel substituted N-phenyl-N′-(2-chloroethyl)ureas either rationally designed as antimicrotubule agents or produced as Table 1 . Antiproliferative Activity (IC 50 ) and Effect of PUB-SOs, PUB-SAs, and cDDP on Cell Cycle Progression a IC 50 is expressed as the concentration of drug inhibiting cell proliferation by 50%.
b For flow cytometry experiments, Jurkat cells were incubated for 24 h in the presence of the selected PUB-SOs and PUB-SAs at a concentration inducing an optimal arrest of cell cycle progression in S-phase. cDDP was used as positive control; n.e., not evaluated.
intermediates in the synthesis of PIB-SOs revealed an unusual arrest of cell cycle progression in S-phase (compounds 4−6 and 10, Table 1 ) instead of the G 2 /M phase, as observed with their known antimicrotubule counterparts. That unexpected S phase arrest induced by this new subset of N-phenyl-N′-(2-chloroethyl)ureas prompted us to determine their structure− activity relationships and to investigate their mechanism of action. o-Tolyl 4-[3-(2-chloroethyl)ureido]benzenesulfonate (4) and 4-hydroxyphenyl 4-[3-(2-chloroethyl)ureido]-benzenesulfonate (10) were selected as molecular templates to initiate the structure−activity relationship study. We first assessed the role and the substitution pattern of the electrophilic CEU group on ring A ( Figure 1 ) via its substitution with a 3-chloropropylurea (CPU) or an ethylurea (EU) moiety, leading to N-phenyl ureidobenzenesulfonate derivatives (PUB-SOs), molecules containing alkylurea moieties. We subsequently replaced the sulfonyl group bridging the phenyl rings A and B of PUB-SOs with a bioisosteric sulfonamide bridge, thereby leading to N-phenylureidobenzenesulfonamides (PUB-SAs). Moreover, we studied the effects of replacing the methyl substituent with an ethyl or propyl group at the C2 position of the B-ring. We also studied the effect of a hydroxyl moiety at the C4 position of the B-ring. The potential antiproliferative activity and effect on cell cycle progression of these novel compounds were assessed in M21 human skin melanoma, estrogen-dependent MCF-7 breast adenocarcinoma, and HT-29 colon adenocarcinoma cell lines. The most potent inhibitors of S-phase progression among these derivatives were assessed for their potential induction of H2AX phosphorylation, which parallels the induction of DNA doublestrand breaks, and for their antitumoral activity in HT-1080 human fibrosarcoma cells grafted onto the CAM assay.
■ RESULTS AND DISCUSSION
Chemistry. Scheme 1 depicts the synthetic pathways used for the preparation of substituted PUB-SO and PUB-SA analogues. These compounds were prepared by nucleophilic addition of the appropriate phenols or anilines to nitrobenzene-1-sulfonyl chloride. Nitrophenyl sulfonates 56−67 and nitrophenylsulfonamides 68−73 were reduced to the corresponding Scheme 1 a cell lines, namely, HT-29 colon carcinoma, M21 skin melanoma, and MCF-7 breast carcinoma cells. These cell lines were selected as representatives of tumors originating from the three germ layers (i.e., endoderm (HT-29), mesoderm (M21), and ectoderm (MCF-7)). Antiproliferative activity was evaluated using the sulforhodamine B method according to the NCI/NIH Developmental Therapeutics Program. 17 The results are summarized in Table 1 and are expressed as the IC 50 . The antiproliferative activity of several PUB-SOs (compounds 4−7, 10, 12, 13, 16, 17, 26, 30, 31, 45−47, and 49) was equivalent to or better than with cisplatin (cis-diamminedichloroplatinum-(II), cDDP). In contrast, the antiproliferative activity of PUBSAs was lower than for PUB-SOs and cDDP. Only two PUBSAs (compounds 20 and 36) showed antiproliferative activity comparable to that observed with cDDP.
Effect on Cell Cycle Progression. Table 1 shows the percentage of Jurkat cells in G0/G1, S, and G2/M phases, respectively, after treatment with PUB-SOs, PUB-SAs, and cDDP for 24 h at optimal concentrations regarding the arrest of cell cycle progression in S-phase. Cell cycle distribution observed for control cells treated with 0.5% DMSO was 43%, 40%, and 17% in G 0 /G 1 , S, and G 2 /M phases, respectively. PUB-SOs 5, 6, 10, 30, 31, 33, 40, 41, 45, and 49 caused an Sphase arrest, thereby increasing the percentage of S-phase cells by 12−27%. PUB-SOs 4, 16, 17, 29, 46, and 47 strongly blocked cell cycle progression and this, to a more efficient extent than cDDP, as measured by an increase in the S-phase fraction of 30−41%. A concentration of 19 μM cDDP blocked 69% of the Jurkat cell population in S-phase. In contrast, PUBSAs did not induce an S-phase block.
Structure−Activity Relationships. As depicted in Table 1 and as previously mentioned, replacing the sulfonyl group bridging phenyl rings A and B with a bioisosteric sulfonamide bridge significantly lowered antiproliferative activity and reduced the effect on cell cycle progression. Consequently, the spatial conformations of the two phenyl rings conferred by the bridge between the two phenyl rings are important for the activity. Moreover, our structure−activity relationship study shows that the substitution pattern of the pharmacophoric moiety on the A-ring is an important factor in the antiproliferative activity and cell cycle arrest caused by a given derivative. Transposition of the pharmacophoric CEU, CPU, and EU moieties from C4 to C3 on the A-ring significantly decreased antiproliferative activity and abolished the effect on cell cycle progression. Thus, derivatives whose Arings have steric hindrance at C3 position with CEU, CPU, or EU in general did not entail S-phase arrest.
Structure−activity relationship studies revealed that the nature of the pharmacophoric substituting group is also important. Derivatives bearing EU and CEU moieties at C4 position of A-ring exhibited antiproliferative activities in the same range and were more potent than their counterparts bearing a CPU moiety. Consequently, steric hindrance at this specific position does not seem to affect the biological activity. Interestingly, compounds 40, 41, 45−47, 49, and 53 bearing an EU moiety were potent antiproliferative agents and arrested cell cycle progression in S-phase. These compounds lack an electrophilic chlorine substituent, which is involved in the mechanism of nucleophilic esterification of acidic peptide residues such as glutamic and aspartic acids. 11, 13 Thus, the presence of a chlorine atom and dipole−dipole interactions are not prerequisites for the biological activity of this group of compounds, unlike the G 2 /M or G 0 /G 1 block that is specifically observed with the N-phenyl-N′-(2-chloroethyl)urea derivatives. 13 This suggests that the mechanism of action of compounds 40, 41, 45−47, 49, and 53 does not likely proceed via nucleophilic protein alkylation. Another most interesting feature of PUB-SOs lies in the fact that the B-ring can accommodate substitution with either a hydroxyl group at C4 or an alkyl (methyl, ethyl, propyl) group at C2 without significant alteration of their cytocidal activity, and therefore, steric hindrances do not affect the C2 position. Thus, we obtained a new class of antiproliferative agents that block the Sphase, with several of its members exhibiting IC 50 values that are similar to or better than in the case of cDDP, used here as a positive control.
Phosphorylation of H2AX. Since the major event occurring in S-phase is DNA replication, we next assessed whether DNA double-strand breaks are involved in the mechanism of action of PUB-SOs. According to current literature, 18−21 phosphorylation of Ser-139 at the C-terminus of histone H2AX (thus yielding γH2AX) occurs upon induction of DNA double-strand breaks. To address the mechanism of action of the novel S-phase inhibitors, we evaluated their ability to induce γH2AX formation. H2AX phosphorylation induced by compounds 4, 16, 17, 29−31, 33, 40, 41, 45−47, and 49, which had displayed the highest antiproliferative activity (IC 50 < 55 μM) and the ability to block >60% of the S-phase fraction was assessed by immunofluorescence. 22, 23 As depicted in Figure  2 , the latter group of compounds, when tested at their respective IC 50 value, induced H2AX phosphorylation in M21 cells. Indeed, γH2AX was detected as nuclear red spots in nuclei (stained in blue using 4′,6-diamidino-2-phenylindole (DAPI)) of cells treated with 4, 16, 17, 29−31, 33, 40, 41, 45− 47, as well as with cDDP, but was absent from control cells. The latter data support the notion that the active PUB-SOs act via the induction of DNA double-strand breaks, which in turn may account for the S-phase cell arrest induced by these compounds. Research is in progress to determine the molecular mechanism responsible for the induction of DNA doublestrand breaks and γH2AX by this category of derivatives.
Antitumoral Activity As Measured with CAM Assays. The most potent PUB-SOs in each series of CEU, CPU, and EU that induce an S-phase block (compounds 4, 10, 16, 17, 30, 45, 46 , and 47) were tested in ovo using the CAM assay. HT-1080 human fibrosarcoma cells were selected because they produce solid tumors that are sensitive to antiangiogenic and antitumoral agents.
24−29 cDDP and CA-4 were used as positive controls. A mixture of Cremophor EL, 99% ethanol, and PBS (1/1/14 v/v) was used as an excipient to inject cDDP, CA-4, and PUB-SOs. cDDP (10 μg/egg) and CA-4 (1 μg/egg) respectively inhibited tumor growth by 46% and 49% and exhibited toxicity in 6% and 21% of the chick embryos. As shown in Figure 3 , compounds 4, 10, 16, 17, 30, and 45−47 administered at 30 μg/egg (except for 4 which was used at 10 μg/egg) significantly inhibited tumor growth. Thus, compounds 10, 30, 45, and 47 respectively inhibited tumor growth by 69%, 68%, 68%, and 65% and exhibited lethality in 15%, 0%, 9%, and 10% of the chick embryos. Compounds 16 and 17 reduced tumor growth by 49%, i.e., to an extent comparable to that of cDDP and CA-4, but were rather toxic toward chick embryos (causing death in 33% and 36% of embryos, respectively). On the other hand, compounds 4 and 46 inhibited tumor growth by 60% and 45%, respectively, while showing low toxicity in chick embryos (with a 15% and 9% death rate, respectively), in a manner similar to that of cDDP and CA-4.
■ CONCLUSION
We have identified and characterized PUB-SOs as a novel class of anticancer agents that block cell cycle progression in S-phase. Structure−activity relationships of PUB-SOs indicate that modification of their sulfonyl group by a bioisosteric sulfonamide moiety, yielding PUB-SAs, abolishes both their antiproliferative and cell cycle blocking activities. The pharmacophoric EU and CEU moieties with a substitution at C4 on aromatic ring A are required to achieve optimal antiproliferative activity and S-phase arrest, whereas substitutions with alkyl groups at C2 or a hydroxyl group at C4 on the B-ring do not significantly affect cytocidal activity. In the series of PUB-SOs herein synthesized, we have identified compounds with an antiproliferative activity and ability to cause S-phase arrest comparable to those of cDDP. Moreover, compounds 4, 16, 17, 29−31, 33, 40, 41, 45−47, and 49 induce H2AX phosphorylation, in support for a mechanism of action that involves DNA double-strand breaks, although the molecular details have yet to be identified. Finally, compounds 4 and 46 are at least as active as cDDP and CA-4 in the CAM assay while displaying little or no toxic effect on chick embryos, suggesting that these compounds might represent a promising new class of anticancer agents.
■ EXPERIMENTAL SECTION
Biological Methods. Antiproliferative Activity. HT-29 colon carcinoma cells, M21 skin melanoma cells, and MCF-7 breast carcinoma cells (all of human origin) were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in high-glucose Dulbecco's minimal essential medium (DMEM) supplemented with 5% (v/v) fetal bovine serum (Hyclone, Logan, UT). The cell lines were maintained at 37°C in a watersaturated atmosphere containing 5% CO 2 . The growth inhibition potency of all compounds was assessed using the procedure recommended by the National Cancer Institute for its drug screening program. 17 Briefly, 96-well microtiter plates were seeded with 75 μL of a suspension of HT-29 (4 × 10 3 ), M21 (3.5 × 10 3 ), or MCF-7 (3 × 10 3 ) cells per well in DMEM. Plates were incubated at 37°C and 5% CO 2 for 24 h. Drugs freshly solubilized in DMSO (40 mM) were diluted in fresh DMEM, and 75 μL aliquots containing serially diluted concentrations of the drug were added. Final drug concentrations ranged from 200 μM to 780 nM. DMSO was maintained at a concentration of <0.5% (v/v) to avoid any related toxicity. Plates were incubated for 48 h, after which growth was stopped by the addition of cold trichloroacetic acid to the wells (10% w/v, final concentration), followed by a 1 h incubation at 4°C. Plates were then washed 5 times with water. An amount of 75 μL of a sulforhodamine B solution (0.1% w/v) in 1% acetic acid was added to each well, and the plates were incubated for 15 min at room temperature. After staining, unbound dye was removed by washing 5 times with 1% acetic acid. Bound dye was solubilized in 20 mM Tris base, and the absorbance was read using an optimal bandwidth (530−568 nm) with a μQuant Universal microplate spectrophotometer (Biotek, Winooski, VT). Readings obtained from treated cells were compared with measurements from control cell plates fixed on treatment day, and the percentage of cell growth inhibition was thus calculated for each drug. The experiments were performed at least twice in triplicate. The assays were considered valid when the coefficient of variation for a given set of conditions and within the same experiment was <10%.
Cell Cycle Analysis. Jurkat E6 human leukemic T-cell lymphoblasts were purchased from the American Type Culture Collection. Cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum. Cells were maintained at 37°C in a water-saturated 5% CO 2 atmosphere. PUB-SOs, PUB-SAs, cDDP, and DMSO were serially diluted in culture medium in a 12-well plate, starting at a concentration 50% above their respective IC 50 toward M21 cells. Next, 4.0 × 10 5 Jurkat cells suspended in culture medium were added to each well and incubated with the drugs for 24 h. Cells were then harvested, washed with PBS, and resuspended in 250 μL of PBS containing 3.0 × 10 5 chicken red blood cells as an internal standard. Cells were fixed by the addition of 750 μL of ice-cold EtOH and stored at −20°C until analysis. Prior to fluorometry, cells were washed with PBS and resuspended in 1 mL of PBS containing 1 μg/ mL DAPI. Fixed cell suspensions were incubated on ice for 1 h, and cell cycle distribution was then analyzed using an LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ).
Immunofluorescence. Cover slides (22 mm × 22 mm) sterilized with 70% (v/v) EtOH were placed in six-well plates. To promote cell adhesion, cover slides were treated with 1.5 mL of a fibronectin solution in PBS (10 μg/mL) for 1 h at 37°C. Slides were then rinsed twice with PBS. M21 cells (1 × 10 5 ) were seeded onto the plates and incubated for 24 h. Cells were then incubated with the test compound at its IC 50 for 24 h at 37°C. The control solution consisted of DMSO dissolved in culture medium (0.5%, v/v). Cells were fixed using 1 mL of formaldehyde at 3.7% and permeabilized by addition of a saponin solution (0.1% in PBS) containing 3% (w/v) BSA (saponin−BSA). Cells were incubated with mouse anti-H2AX pS139 antibody (Millipore, Billerica, MA). Cover slides were next incubated for 3 h at room temperature and then washed twice with PBS supplemented with 0.05% (v/v) Tween 20 (PBS-T). Saponin−BSA containing goat anti-mouse IgG conjugated to AlexaFluor 594 (Invitrogen, Burlington, Ontario, Canada), and DAPI (Sigma, Oakville, Ontario, Canada) (0.3 μg/mL) was then added. The cover slides were incubated for 2 h at room temperature and then washed twice with PBS-T and twice with PBS. The cover slides were mounted with polyvinyl alcohol−1,4,-diazobicyclo[2.2.2]octane (10−2.5%, v/v) in buffer (5% (v/v) glycerol and 25 mM Tris buffer, pH 8.7) (Sigma, Oakville, Ontario, Canada). Cells were visualized using an epifluorescence microscope (Olympus BX51, Center Valley, PA) with a Qimaging RETIGA EXi camera (Qimaging, Surrey, British Columbia, Canada).
CAM Assay. Human HT-1080 fibrosarcoma cells were cultured in Dulbecco's minimal essential medium containing 58 mM NaHCO 3 25 mM D-glucose, 4 mM L-glutamine, and 0.11 mM sodium pyruvate supplemented with 5% (v/v) fetal bovine serum. Cells were maintained at 37°C in a water-saturated, 5% CO 2 atmosphere. HT-1080 cells were used to assess the antitumoral activity of candidate drugs in the CAM assay. Briefly, on day 0, freshly fertilized chicken eggs were purchased from Couvoirs Victoriaville (Victoriaville, Quebec, Canada). The eggs were incubated for 10 days in a Pro-FI egg incubator (Lyon Electric, Chula Vista, CA) fitted with an automatic egg turner before being transferred to a Roll-X static incubator for the rest of the incubation period. Eggs were kept at 37°C in a 60% relative humidity atmosphere for the entire incubation period. By use of a hobby drill (Dremel, Racine, WI), a hole was drilled on the side of the egg, and negative pressure was applied to create a new air sac. A window was opened in this new air sac and was covered with transparent adhesive tape to prevent contamination. A freshly prepared HT-1080 cell suspension (40 μL, 3.5 × 10 5 cells/egg) was applied directly on the freshly exposed CAM tissue. On day 11, drugs dissolved in DMSO (40 μM) were extemporaneously diluted at the required concentrations in the excipient (Cremophor EL/99% ethanol/PBS, 1/1/14 v/v). The drug solution (100 μL) was injected into a vein under the CAM. Each experimental group contained 10− 12 eggs that were incubated until day 17. Embryos were euthanized by cooling at 4°C for at least 4 h. Tumors were collected, and tumor wet weight was recorded. The number of dead embryos and signs of toxicity from the different groups were also recorded.
Chemical Procedures. General. Proton NMR spectra were recorded on a Bruker AM-300 spectrometer (Bruker, Germany). Chemical shifts (δ) are reported in parts per million. Reactions using microwave heating were performed with an Initiator system (Biotage, Charlottesville, VA). IR spectra were recorded with a Magna FT-IR spectrometer (Nicolet Instrument Inc., Madison, WI). Uncorrected melting points were determined on an electrothermal melting point apparatus. HPLC analyses of compounds 4−8 and 10 were performed using an Acquity UPLC sample with binary solvent manager equipped with a Quattro Premier XE tandem quadrupole mass spectrometer (Waters, Milford, MA). Compounds were analyzed with a Waters BECH C18 reversed-phase column (1.7 μm, 2.1 mm × 50 mm, 50°C) and eluted within 7 min with a MeOH/H 2 O linear gradient containing 0.1% TFA at 0.6 mL/min. HPLC analysis of other end compounds was performed using a Prominence LCMS-2020 system with binary solvent equipped with a UV/vis photodiode array (Shimadzu, Columbia, MD). Compounds were eluted in 30 min on an Alltech Alltima C18 reversed-phase column (5 μm, 250 mm × 4.6 mm) equipped with an Alltech Alltima C18 precolumn (5 μm, 7.5 mm × 4.6 mm) with a MeOH/H 2 O linear gradient at 1.0 mL/min. Purity of the final compounds was >95%. All reactions were performed under a dried Ar atmosphere. All chemicals were supplied by Aldrich Chemicals (Milwaukee, WI) or VWR International (Mont-Royal, Quebec, Canada) and used as received unless specified otherwise. Liquid flash chromatography was performed on silica gel F60, 60A, 40−63 μm supplied by Silicycle (Quebec, Canada) using a FPX flash purification system (Biotage, Charlottesville, VA) and using solvent mixtures expressed as v/v ratios. Solvents and reagents were used without purification unless specified otherwise. The progress of all reactions was monitored by TLC on precoated silica gel 60 F254 TLC plates (VWR). The chromatograms were viewed under UV light at 254 and/or 265 nm.
General Procedure for the Synthesis of Compounds 4−55. Method A. The appropriate isocyanate (1.2 mmol) was added dropwise to the appropriate aniline (1.0 mmol) in dry methylene chloride or dry tetrahydrofuran (10 mL) under an Ar atmosphere. The reaction mixture was stirred at room temperature for 7 days. The solvent was evaporated under reduced pressure, and the compound was purified by flash chromatography.
Method B. 2-Chloroethyl isocyanate (1.2 mmol) and 4-dimethylaminopyridine were added dropwise to a solution of the appropriate aniline (1.0 mmol) in dry tetrahydrofuran (10 mL) under an Ar atmosphere. The reaction mixture was heated to reflux and stirred for 7 days. After the mixture was cooled to room temperature, the solvent was evaporated under reduced pressure and the crude compound was purified by flash chromatography.
Method C. The appropriate isocyanate (2.0 mmol) was added dropwise to appropriate aniline (1.0 mmol) in dry acetonitrile or dry tetrahydrofuran (10 mL). The reaction was performed either in the absence or presence of pyridine (1 mmol). The reaction mixture was stirred from 60 to 130°C under microwave heating (100 W) for 15− 50 min. The solvent was evaporated and the residue dissolved in ethyl acetate. The solution was washed with hydrochloric acid (1 N) and brine, dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness.
Method D. The appropriate isocyanate (1.2 mmol) was added dropwise to the appropriate aniline (1.0 mmol) in dry acetonitrile (10 mL) under an Ar atmosphere. Pyridine (1.0 mmol) was added to the solution. The reaction mixture was stirred at room temperature for 7 days. The solvent was evaporated under reduced pressure, and the compound was purified by flash chromatography.
Method E. The appropriate compound (9, 14, 27, 32, 43, or 48 (0.1 mmol)) was dissolved in dry tetrahydrofuran (5 mL). Tetrabutylammonium fluoride (1M) in dry THF was added dropwise. The mixture was stirred at room temperature for 24 h. The solvent was evaporated and the residue dissolved with ethyl acetate (40 mL). The solution was washed with 40 mL of HCL (1 N), brine, dried over Na 2 SO 4 , filtered, and evaporated to dryness. The crude product was purified by flash chromatography. 
-M e t h o x y p h e n y l -[ 3 -( 2 -C h l o r o e t h y l ) u r e i d o ] -benzenesulfonate (7)
. Method A in THF was used. The crude product was purified by flash chromatography (silica gel, methylene chloride to methylene chloride/ethyl acetate (80: 20) 154.6, 143.4, 140.7, 135.4, 129.7, 124.5, 123.2, 122.0, 120.7, 117.9,  35.1, 25.6, 18.1, 15.2, −4 .5.
-[ 3-( 2-C h l or oe t hy l )u r e i d o ]-N -(2 -p ro p y l ph e n y l )-benzenesulfonamide (23

-E t h y l p h e n y l 3 -[ 3 -( 3 -C h l o r o p r o p y l ) u r e i d o ] -benzenesulfonate (25). Method C in dry MeCN
-P r o p y l p h e n y l 3 -[ 3 -( 3 -C h l o r o p r o p y l ) u r e i d o ] -benzenesulfonate (26
-H y d r o x y p h e n y l 3 -[ 3 -( 3 -C h l o r o p r o p y l ) u r e i d o ] -benzenesulfonate (28)
. Method E
-E t h y l p h e n y l 4 -[ 3 -( 3 -C h l o r o p r o p y l ) u r e i d o ] -benzenesulfonate (30)
4-Hydroxyphenyl 3-(3-Ethylureido)benzenesulfonate (44). Method E was used. The crude product was purified by flash chromatography (silica gel, ethyl acetate to ethyl acetate/methanol (90:10)). Yield, 50%; white sticky solid. IR ν: 1649 (CO) cm For method F, the 3-nitrobenzene-1-sulfonyl chloride or 4-nitrobenzene-1-sulfonyl chloride (7.5 mmol) was dissolved in dry methylene chloride (20 mL) under a dry Ar atmosphere. The selected phenol or aniline (7.5 mmol) and trietylamine were then added dropwise to the solution. The reaction mixture was stirred for 24 h at room temperature. The solvent was evaporated and the residue dissolved in ethyl acetate. The solution was washed with 1 N HCl, 1 N NaOH, brine, dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness.
For method G, the 3-nitrobenzene-1-sulfonyl chloride or 4-nitrobenzene-1-sulfonyl chloride (8 mmol) was dissolved in dry acetonitrile (10 mL) under an Ar atmosphere. The relevant aniline (8 mmol) and 4-dimethylaminopyridine were successively added dropwise, and the mixture was stirred for 48 h at room temperature. The solvent was evaporated and the residue dissolved in ethyl acetate. The solution was washed with hydrochloric acid (1 N), brine, dried over Na 2 SO 4 , filtered, and evaporated to dryness. General Procedure for the Synthesis of Compounds 74−91. The appropriate nitro compound (2.0 mmol) was dissolved in a mixture of EtOH and H 2 O (40 mL, 10:1). Powdered iron (8.0 mmol) and five drops of hydrochloric acid (12 M) were added. The mixture was refluxed overnight. After the mixture was cooled at room temperature, the solvent was evaporated. HCl (1 N, 100 mL) was added and the mixture was extracted with ethyl acetate (100 mL). The organic solutions were pooled, washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. 4-Methoxyphenyl 4-Aminobenzenesulfonate (77). To a solution of the nitro compound 59 (2.0 mmol) in ethanol (40 mL) was added stannous chloride dihydrate (12.0 mmol), and the mixture was refluxed for 6 h. After the mixture was cooled at room temperature, the solvent was evaporated. The residue was then taken up in 300 mL of 1 N NaOH and extracted with ether (200 mL). The combined organic extracts were washed with brine, dried over Na 2 SO 4 
